BlinkLab LimitedASX: BB1

Positive Results in Genetic Autism Study Ahead of Schedule

· Issued by BlinkLab Limited via ASX

Filed with ASX · · 7 pages · English

Summary by 6ix AI

The study utilized smartphone-based assessments to measure neurophysiological differences, supporting the biological relevance of BlinkLab's technology in diagnosing neurodevelopmental disorders. These findings open potential avenues for therapeutic development and underscore the importance of objective measures in clinical trials for autism.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX:BB1 ASX Announcement 11 November 2026 BlinkLab Reports Positive Results in Genetic Autism Study, Ahead of Schedule Highlights ? Strong multi-domain biomarker signal in SHANK2-related autism: Individuals with a SHANK2 mutation (n = 8) showed significant differences in BlinkLab smartphone-tests...

BlinkLab Limited on 6ix

Earlier from BlinkLab

All BlinkLab news releases